Two old antibiotics together revive a frontline TB drug in lab tests, IISc study finds
Researchers at the Indian Institute of Science (IISc) in Bengaluru have found that pairing two long-known antibiotics — isoniazid and vancomycin — can restore the power of a frontline tuberculosis drug against bacteria that had learned to resist it.
Isoniazid is one of the cornerstones of TB treatment, but mutations can stop the bacterium from activating it, making the drug useless. Vancomycin, meanwhile, normally cannot get through the TB germ’s thick, waxy cell wall. In laboratory experiments, the two together weakened that wall and killed resistant bacteria: across samples taken from people with drug-resistant TB, the combination cut bacterial growth by more than 90% in most isolates tested.
In mice infected with multidrug-resistant TB, the combination reduced bacterial levels roughly tenfold in the lungs and spleen after 10 days, while neither drug alone had much effect. The study was published in November 2026 in the peer-reviewed journal Microbiology Spectrum.
The need is enormous. TB still sickens more than ten million people a year worldwide, and India alone accounts for roughly a quarter of global cases. When standard drugs fail, patients face longer treatments with harsher side effects.
Important caution: this combination has not been tested in people. It is not a treatment, and no patient should change, add or combine TB medicines on the basis of this news. Human trials on safety — including vancomycin’s known kidney risks — dosing and long-term cure rates must come first. If those trials succeed, doctors could gain a new tool built from medicines that already exist.
دو پرانی اینٹی بایوٹکس کے ملاپ سے ٹی بی کی دوا دوبارہ مؤثر ہونے کی امید
بھارتی ادارے IISc کے سائنسدانوں نے دریافت کیا ہے کہ دو معروف اینٹی بایوٹکس، آئسونیازڈ اور وینکومائسن، کو ملا کر استعمال کرنے سے ٹی بی کی مزاحم جراثیم کے خلاف دوا دوبارہ مؤثر ہو سکتی ہے۔ تجربہ گاہ میں یہ ملاپ جراثیم کی افزائش میں 90 فیصد سے زائد کمی لایا اور چوہوں پر بھی حوصلہ افزا نتائج ملے۔ تاہم یہ تحقیق ابھی انسانوں پر آزمائی نہیں گئی — یہ علاج نہیں ہے، اور مریض اپنی دوا خود تبدیل نہ کریں۔
Should more research money go into finding new uses for old medicines, instead of only inventing new ones? What do you think?